Ubs Group Ag Tcr2 Therapeutics Inc. Transaction History

Ubs Group Ag

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$1.0 - $1.62 $234 - $379	234 New	234 $0
Q3 2022 Nov 10, 2022	BUY	$1.86 - $3.75 $6,880 - $13,871	3,699 New	3,699 $7,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $23,282 - $45,691	-9,701 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $206,223 - $375,525	-45,027 Reduced 82.27%	9,701 $45,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $333,093 - $724,201	39,466 Added 258.59%	54,728 $466,000
Q2 2021 Aug 13, 2021	SELL	$16.41 - $24.71 $636,839 - $958,945	-38,808 Reduced 71.77%	15,262 $251,000
Q1 2021 May 12, 2021	BUY	$20.38 - $34.07 $1.07 Million - $1.79 Million	52,582 Added 3533.74%	54,070 $1.19 Million
Q4 2020 Feb 11, 2021	BUY	$19.0 - $32.63 $22,971 - $39,449	1,209 Added 433.33%	1,488 $46,000
Q3 2020 Nov 12, 2020	SELL	$13.1 - $20.69 $64,059 - $101,174	-4,890 Reduced 94.6%	279 $6,000
Q2 2020 Jul 31, 2020	SELL	$6.51 - $16.85 $10,845 - $28,072	-1,666 Reduced 24.37%	5,169 $79,000
Q1 2020 May 01, 2020	SELL	$6.01 - $16.01 $45,784 - $121,964	-7,618 Reduced 52.71%	6,835 $53,000
Q4 2019 Feb 14, 2020	BUY	$12.17 - $17.88 $66,703 - $98,000	5,481 Added 61.09%	14,453 $206,000
Q3 2019 Nov 14, 2019	BUY	$10.15 - $19.53 $74,856 - $144,033	7,375 Added 461.8%	8,972 $135,000
Q2 2019 Aug 14, 2019	BUY	$13.64 - $20.97 $21,346 - $32,818	1,565 Added 4890.63%	1,597 $23,000
Q1 2019 May 14, 2019	BUY	$15.01 - $22.15 $480 - $708	32 New	32 $1,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.